Abiraterone acetate (AA) can be safely administered for long periods without concurrent steroids in patients with advanced castration-resistant prostate cancer (CRPC), according to research presented here at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC). AA reduces levels of testosterone, oestradiol, and cortisol, but it increases levels of adrenocorticotropic hormone, deoxycorticosterone, and corticosterone, which could lead to hypokalaemia, hypertension, and fluid retention.

For the full story, Click Here

Sorafenib therapy is safe and effective, with evidence of long-lasting disease control in elderly patients with metastatic renal cell carcinoma (mRCC), according to research presented at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC). On the basis of increasing incidence of RCC with age, the objective of this retrospective, subset analysis was to assess the safety and efficacy of sorafenib in patients older than 65 years of age.

For the full story, Click Here